

**Rheumatology Infusion
Enrollment Form**



FACTOR ONE SOURCE
FAST
PHARMACY

Powered By: InfuCare Rx

Phone: 1-833-367-3278
Fax: 844-504-3278
Website: www.FOSRXFAST.com

Louisiana Office
2400 Veterans Memorial Blvd., Suite 480
Kenner, LA 70062

PATIENT INFORMATION				PRESCRIBER INFORMATION			
Name:				Prescribing Practitioner:		NPI:	
Address:				Address:			
City:		State/Zip:		City:		State/Zip:	
Telephone:		DOB:	M	F	Office:		DEA:
Language Preference:			Wt:	Ht:	Contact:	Phone:	Fax:

PRIMARY INSURANCE INFORMATION						
Member Name:			M	F	DOB:	
Address:			City:			
State:		Zip:	Telephone:		Alt. Telephone:	
Member ID:			Rx Group #:		BIN#:	
PCN#:		Customer Service #:				

PRESCRIPTION					
New	Refill	Ship by:	Ship to: Patient's Home Doctor's Office Other: _____		

Drug	Directions	Quantity	Refills
Actemra®	Infuse: 80mg 200mg 400mg every 4 weeks	1 month supply	
Benlysta®	120mg/vial 400mg/vial Loading Dose: Infuse _____ mg at weeks 0,2, and 4 Maintenance Dose: Infuse _____ mg every 4 weeks	4 week supply	
Boniva®	3mg/ml Inject 3 mg every 3 months	1 month supply	
Cimzia®	200mg/vial Infuse: _____	1 month supply	
Krystexxa®	8mg/vial Infuse: _____	1 month supply	
Orencia®	250mg vial Infuse: _____	1 month supply	
Prolia®	60mg Inject 60mg subq every 6 months	1 month supply	
Reclast®	5mg/100ml Infuse: _____	1 month supply	
Remicade®	100mg vial Infuse: _____	1 month supply	
Rituxan®	100mg vial 500mg vial Infuse: _____	1 month supply	
Simponi Aria®	50mg/4ml Infuse: _____	1 month supply	
Stelara®	130 mg/26 mL Vials Pre-filled Syringe Weight Required: _____ 45 mg/0.5 mL Vials 90 mg/mL Vial INITIAL INTRAVENOUS DOSAGE: A single intravenous infusion using weight based dosing: Up to 55g=260mg (2 vials), >55g to 85kg=390 mg (3 vials), >85kg=520 mg (4 vials) MAINTENANCE: Inject 90 mg SQ 8 weeks after intial dose, then every 8 weeks thereafter (1 syringe) SUBCUTANEOUS DOSAGE: ≤ 100 kg: 45 mg subQ initially and then 4 weeks later, 45 mg subQ every 12 weeks after >100 kg: 90 mg subQ initially and then 4 weeks later, 90 mg subQ every 12 weeks after Inject 300 mg subQ week 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 dosage is given as 2 150 mg injections		

DIAGNOSIS AND CLINICAL INFORMATION			
***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY			
M06.9 Rheumatoid Arthritis	L40.52 Psoratic Arthritis	TB/PPD test: Positive Negative	Date Read: _____
M45.9 Ankylosing Spondylitis	M32.10 Systemic Lupus Erythematosus	Patient Weight: _____ kg lbs	Height: _____ cm in
K50.00 Crohn's Disease	Other: _____	Allergies: _____	Lab Data: _____

Prior Medication Failed: _____	Additional Clinical Information:		
Length of Treatment: _____			
Reason for Discontinuation: _____			

PRESCRIBING PRACTITIONER SIGNATURE	
To Prescribing Practitioner: By signing this form and utilizing our services, you are also authorizing FOSRX/FAST to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies and co-pay foundations.	
Prescribing Practitioner Signature: _____	Date: _____